Seroprevalence of Cytomegalovirus Infection and Associated Risk Factors among Human Immunodeficiency Virus Infected Patients Attending Thika Level 5 Hospital, Kenya
Cytomegalovirus (CMV) is an important pathogen in immunocompromised individuals. Coupled with Human Immunodeficiency Virus (HIV), it causes end organ diseases leading to increased morbidity and mortality in the population. The prevalence of Cytomegalovirus infection is above 93% in HIV infected children in Kenya. Despite, a high Cytomegalovirus seroprevalence found in children, few studies have documented CMV in adults. This study was done to determine the seroprevalence of CMV infection and its associated risk factors among HIV patients attending Thika level 5 Hospital in Kiambu County, Kenya. The study also evaluated the effect CMV infection on the immunity of HIV infected patients. A cross-sectional study involving 163 HIV positive participants from different age groups was carried out. A questionnaire was used to assess the socio-demographic and specific risk factors associated with cytomegalovirus. Blood was collected and analyzed for CD4 counts, CMV IgG and IgM. The seroprevalence of CMV was found to be 89% (CMV IgG) while the incidence was 10.4% (CMV IgM). The study found that CMV infection leads to more suppression of the immunity among the HIV infected patients. In addition, education, economic status, having other sexual transmitted infections, sharing drinks, immune status and blood transfusion were associated with CMV infection (p < 0.05). The study recommends adoption of CMV screening services and education on CMV risk factors as CMV infection preventive strategies.
References
[1]
Mocarski, E.S., Shenk, T. and Pass, R.F. (2007) Cytomegalovirus. In: Knipe. D.M. and Howley, P.M., Eds., Fields Virology, 5th Edition, Lippincott Williams & Wilkins, Philadelphia, 2701-2772.
[2]
Griffiths, P.D. and Emery, V.C. (1997) Cytomegalovirus. In: Richman, D.D., Whitley, R.J. and Hayden, F.G., Eds., Clinical Virology, Churchill Livingstone, New York, 445-470.
[3]
Mocarski (1993) Cytomegalovirus Biology and Replication. The Human Herpesviruses. Raven Press, New York, 173-226.
[4]
Cheesbrough, M. (2005) Human Immunodeficiency Virus. In: District Laboratory Practice in Tropical Countries, 2nd Edition, Cambridge University Press, Cambridge, 253-255.
[5]
Hummel, M. and Abecassis, M.M. (2002) A Model for Reactivation of CMV from Latency. Journal of Clinical Virology, 25, 123-136.
http://www.sciencedirect.com/science/article/pii/S1386653202000884 https://doi.org/10.1016/S1386-6532(02)00088-4
[6]
World Health Organization (2016) Global Aids up to Date. World Health Organization. Geneva 27 Switzerland.
[7]
Salmon-Céron, D., Mazeron, M.C., Chaput, S., Boukli, N., Senechal, B., Houhou, N., et al. (2000) Plasma Cytomegalovirus DNA, pp65 Antigenaemia and a Low CD4 Cell Count Remain Risk Factors for Cytomegalovirus Disease in Patients Receiving Highly Active Antiretroviral Therapy. AIDS, 14, 1041-1049.
http://www.ncbi.nlm.nih.gov/pubmed/10853987 https://doi.org/10.1097/00002030-200005260-00017
[8]
Wohl, D.A., Kendall, M.A., Andersen, J., Crumpacker, C., Spector, S.A., Feinberg, J., et al. (2009) Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030. HIV Clinical Trials, 10, 143–152. https://doi.org/10.1310/hct1003-143
[9]
Chakraborty, R., Rees, G., Bourboulia, D., Cross, A.M., Dixon, J.R., D’Agostino, A., et al. (2003) Viral Coinfections among African Children Infected with Human Immunodeficiency Virus Type 1. Clinical Infectious Diseases, 36, 922-924.
http://cid.oxfordjournals.org/content/36/7/922.short
https://doi.org/10.1086/368207
[10]
Slyker, J.A., Lohman-Payne, B.L., John-Stewart, G.C., Maleche-Obimbo, E., Emery, S., Richardson, B., et al. (2009) Acute Cytomegalovirus Infection in Kenyan HIV-Infected Infants. AIDS, 23, 2173-2181.
https://doi.org/10.1097/QAD.0b013e32833016e8
[11]
Maingi, Z. and Nyamache, A.K. (2014) Seroprevalence of Cytomegalo Virus (CMV) among Pregnant Women in Thika, Kenya. BMC Research Notes, 7, 794.
http://www.biomedcentral.com/1756-0500/7/794/ https://doi.org/10.1186/1756-0500-7-794
[12]
Akinbami, A.A., Akanmu, A.S., Adeyemo, T.A., Wright, K.O., Dada, M.O. and Dosunmu, A.O. (2010) Cytomegalovirus Antibodies amongst Immunocompromised (HIV) Patients at Lagos University Teaching Hospital (LUTH) Idi-Araba, Lagos. Journal of Medicine, 11, 151-154.
http://www.banglajol.info/index.php/JOM/article/viewArticle/5462 https://doi.org/10.3329/jom.v11i2.5462
[13]
Njeru, D.G., Mwanda, W.O., Kitonyi, G.W. and Njagi, E.C. (2009) Prevalence of Cytomegalovirus Antibodies in Blood Donors at the National Blood Transfusion Centre, Nairobi. East African Medical Journal, 86, S58-S61.
http://www.ncbi.nlm.nih.gov/pubmed/21591511
[14]
Chaudhari, C.N. and Bindra, M.S. (2009) Seroprevalence of Cytomegalovirus among Voluntary Blood Donors. Medical Journal Armed Forces India, 65, 252-254.
https://doi.org/10.1016/S0377-1237(09)80016-6
[15]
Khairi, S.I., Intisar, K.S., Enan, K.H., Ishag, M.Y., Baraa, A.M. and Ali, Y.H. (2013) Seroprevalence of Cytomegalovirus Infection among Pregnant Women at Omdurman Maternity Hospital, Sudan. J Med. Lab Diagn., 4, 45-49.
[16]
Izetiégouma Maiga, I., Tounkara, A., Coulibaly, G. and Kouriba, B. (2003) Seroprevalence of the Human Cytomegalovirus among Blood Donors and AIDS Patients in Bamako. Cahiers Sante.
http://resolver.lib.washington.edu/resserv?sid=EMBASE&issn=11575999&id=doi:&atitle= Seroprevalence+of+the+human+cytomegalovirus+among+blood+donors+and+AIDS+patients+ in+Bama
[17]
Picone, O., Vauloup-Fellous, C., Cordier, A.G., Parent Du Chatelet, I., Senat, M.V., Frydman, R. and Grangeot-Keros, L. (2009) A 2-Year Study on Cytomegalovirus Infection during Pregnancy in a French Hospital. BJOG: An International Journal of Obstetrics and Gynaecology, 116, 818-823.
[18]
Dowd, J.B., Aiello, E. and Alley, D.E. (2009) Socioeconomic Disparities in the Seroprevalence of Cytomegalovirus Infection in the US Population: NHANES III. Epidemiology and Infection, 137, 58-65. https://doi.org/10.1017/S0950268808000551
[19]
Forsgren, M. (2009) Prevention of Congenital and Perinatal Infections. Eurosurveillance, 14, 2-4.
[20]
Fowotade, A., Okonko, I.O., Agbede, O.O. and Suleiman, S.T. (2015) High Seropositivity of IgG and IgM Antibodies against Cytomegalovirus (CMV) among HIV-1 Seropositive Patients in Ilorin, Nigeria. African Health Sciences, 15, 1-9.
https://doi.org/10.4314/ahs.v15i1.1
[21]
Osti, N.M., Pestana De Castro, A.F. and Costallat Ricci, L. (1998) Research of Antigen and Antibodies from Retroviruses, CMV and HBV among Prisoners of the Penitentiary Complex of the Region of Campinas, SP, Brazil. Revista Do Instituto de Medicina Tropical de Sao Paulo, 40, 209-213.
https://doi.org/10.1590/S0036-46651998000400001
[22]
Lifson, A.R., Krantz, E.M., Eberly, L.E., Dolan, M.J., Marconi, V.C., Weintrob, A.C., Agan, B.K., et al. (2011) Long-Term CD4+ Lymphocyte Response Following HAART Initiation in a U.S. Military Prospective Cohort. AIDS Research and Therapy, 8, 2. https://doi.org/10.1186/1742-6405-8-2
[23]
Mermin, J., Were, W., Ekwaru, J.P., Moore, D., Downing, R., Behumbiize, P., Bunnell, R., et al. (2008) Mortality in HIV-Infected Ugandan Adults Receiving Antiretroviral Treatment and Survival of Their HIV-Uninfected Children: A Prospective Cohort Study. The Lancet, 371, 752-759.
http://www.sciencedirect.com/science/article/pii/S014067360860345
https://doi.org/10.1016/S0140-6736(08)60345-1
[24]
Clarke, L.M., Duerr, A., Feldman, J., Sierra, M.F., Daidone, B.J. and Landesman, S.H. (1996) Factors Associated with Cytomegalovirus Infection among Human Immunodeficiency Virus Type 1-Seronegative and -Seropositive Women from an Urban Minority Community. The Journal of Infectious Diseases, 173, 77-82.
https://doi.org/10.1093/infdis/173.1.77
[25]
Stadler, L.P., Bernstein, D.I., Callahan, S.T., Ferreira, J., Gorgone Simone, G.A., Edwards, K.M., Rosenthal, S.L., et al. (2010) Seroprevalence of Cytomegalovirus (CMV) and Risk Factors for Infection in Adolescent Males. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 51, e76-e81. https://doi.org/10.1086/656918
